FDA Approves Pirtobrutinib for Previously Treated CLL/SLL FDA Approves Pirtobrutinib for Previously Treated CLL/SLL

The approval is the second this year for the reversible, highly selective kinase inhibitor following a January approval in mantle cell lymphoma.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news